|Bid||4.26 x 1800|
|Ask||4.29 x 1000|
|Day's Range||4.2200 - 4.4400|
|52 Week Range||4.2000 - 8.7800|
|Beta (3Y Monthly)||1.43|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.55|
NEW YORK and MELBOURNE, Australia, Nov. 26, 2018 -- Tasly Pharmaceutical Group and Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the first Joint Steering.
MELBOURNE, Australia and NEW YORK, Nov. 15, 2018 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported strong financial results and provided operational highlights for the.
NEW YORK and MELBOURNE, Australia, Nov. 15, 2018 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will report financial results for the quarter ended September 30, 2018 in a.
NEW YORK and MELBOURNE, Australia, Nov. 11, 2018 -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that results from a 159-patient randomized, sham-controlled Phase 2.
NEW YORK and MELBOURNE, Australia, Nov. 09, 2018 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) will host a webcast to discuss the results of the Phase 2b trial evaluating its.
Nasdaq:MESO) today announced it has expanded its partnership with JCR Pharmaceuticals Co. Ltd. in Japan for wound healing in patients with Epidermolysis Bullosa (EB). JCR has received Orphan Designation for the allogeneic mesenchymal stem cell (MSC) product TEMCELL HS Inj1 in the treatment of EB. Based on promising results from an investigator-initiated trial in Japan, JCR intends to seek label extension for TEMCELL in Japan beyond its existing approval for the treatment of acute graft versus host disease.
NEW YORK, Oct. 22, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Mesoblast has received US$40 million (AUD$57 million) from Tasly, comprising an upfront technology access fee of US$20 million and an equity purchase of US$20 million for which Mesoblast Limited has issued 14,464,259 fully paid ordinary shares to Tasly. As consideration, Tasly has received exclusive rights and will fund all development, manufacturing and commercialization activities in China for MPC-150-IM for the treatment and prevention of chronic heart failure and MPC-25-IC for the prevention and treatment of acute myocardial infarction.
Eric A. Rose, M.D., biotech and medical device business leader as well as world-renowned cardiac surgeon and scientist who performed the landmark achievement of the first.
NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-controlled Phase 2b trial.
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
NEW YORK and MELBOURNE, Australia, Sept. 20, 2018-- Mesoblast Limited today announced continued strong survival outcomes through Day 180 in children with steroid refractory acute Graft Versus Host Disease ...
Mesoblast Limited’s (ASX:MSB): Mesoblast Limited develops cell-based medicines. With the latest financial year loss of -US$76.8m and a trailing-twelve month of -US$41.6m, the AU$750.5m market-cap alleviates its loss by movingRead More...
Mesoblast (NASDAQ: MESO ) releases its next round of earnings Wednesday. Here's Benzinga's essential guide to Mesoblast's Q4 earnings report. Earnings and Revenue Analysts are predicting Mesoblast will ...
July 17 (Reuters) - Tasly Pharmaceutical Group Co Ltd : * SAYS IT SIGNS AGREEMENT TO INVEST $20 MILLION IN AUSTRALIA'S MESOBLAST LIMITED Source text in Chinese: https://bit.ly/2L387MD Further company coverage: ...
The Australian company unveiled data from a study evaluating a potential treatment for children with steroid refractory acute Graft Versus Host Disease.